These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 38446351)

  • 1. Sacituzumab Govitecan: A Review in Unresectable or Metastatic HR+/HER2- Breast Cancer.
    Kang C
    Target Oncol; 2024 Mar; 19(2):289-296. PubMed ID: 38446351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial.
    Rugo HS; Bardia A; Marmé F; Cortés J; Schmid P; Loirat D; Trédan O; Ciruelos E; Dalenc F; Gómez Pardo P; Jhaveri KL; Delaney R; Valdez T; Wang H; Motwani M; Yoon OK; Verret W; Tolaney SM
    Lancet; 2023 Oct; 402(10411):1423-1433. PubMed ID: 37633306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A plain language summary of the TROPiCS-02 study in patients with breast cancer (HR-positive/HER2-negative).
    Rugo HS; Bardia A; Marmé F; Cortés J; Schmid P; Spears PA; Tolaney SM
    Future Oncol; 2024 Apr; 20(11):635-651. PubMed ID: 38270051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
    Bardia A; Hurvitz SA; Tolaney SM; Loirat D; Punie K; Oliveira M; Brufsky A; Sardesai SD; Kalinsky K; Zelnak AB; Weaver R; Traina T; Dalenc F; Aftimos P; Lynce F; Diab S; Cortés J; O'Shaughnessy J; Diéras V; Ferrario C; Schmid P; Carey LA; Gianni L; Piccart MJ; Loibl S; Goldenberg DM; Hong Q; Olivo MS; Itri LM; Rugo HS;
    N Engl J Med; 2021 Apr; 384(16):1529-1541. PubMed ID: 33882206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer.
    Rugo HS; Bardia A; Marmé F; Cortes J; Schmid P; Loirat D; Trédan O; Ciruelos E; Dalenc F; Pardo PG; Jhaveri KL; Delaney R; Fu O; Lin L; Verret W; Tolaney SM
    J Clin Oncol; 2022 Oct; 40(29):3365-3376. PubMed ID: 36027558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon.
    Furlanetto J; Marmé F; Loibl S
    Future Oncol; 2022 Sep; 18(28):3199-3215. PubMed ID: 36069628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.
    Bardia A; Mayer IA; Vahdat LT; Tolaney SM; Isakoff SJ; Diamond JR; O'Shaughnessy J; Moroose RL; Santin AD; Abramson VG; Shah NC; Rugo HS; Goldenberg DM; Sweidan AM; Iannone R; Washkowitz S; Sharkey RM; Wegener WA; Kalinsky K
    N Engl J Med; 2019 Feb; 380(8):741-751. PubMed ID: 30786188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial.
    Kalinsky K; Diamond JR; Vahdat LT; Tolaney SM; Juric D; O'Shaughnessy J; Moroose RL; Mayer IA; Abramson VG; Goldenberg DM; Sharkey RM; Maliakal P; Hong Q; Goswami T; Wegener WA; Bardia A
    Ann Oncol; 2020 Dec; 31(12):1709-1718. PubMed ID: 32946924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health-related quality of life with sacituzumab govitecan in HR+/HER2- metastatic breast cancer in the phase III TROPiCS-02 trial.
    Rugo HS; Schmid P; Tolaney SM; Dalenc F; Marmé F; Shi L; Verret W; Shah A; Gharaibeh M; Bardia A; Cortes J
    Oncologist; 2024 Sep; 29(9):768-779. PubMed ID: 38748596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer.
    Weiss J; Glode A; Messersmith WA; Diamond J
    Expert Rev Anticancer Ther; 2019 Aug; 19(8):673-679. PubMed ID: 31398063
    [No Abstract]   [Full Text] [Related]  

  • 11. Tackling metastatic triple-negative breast cancer with sacituzumab govitecan.
    Schreiber AR; Andress M; Diamond JR
    Expert Rev Anticancer Ther; 2021 Dec; 21(12):1303-1311. PubMed ID: 34651524
    [No Abstract]   [Full Text] [Related]  

  • 12. Case report of sacituzumab govitecan-hziy-induced neutropenia in a patient with metastatic triple-negative breast cancer and a uridine diphosphate glucuronosyltransferase family 1 member A1 poor metabolizer genotype.
    Baek G; Jung L; Duong A; Gralow J
    J Oncol Pharm Pract; 2022 Apr; 28(3):710-716. PubMed ID: 34761708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities.
    Spring LM; Nakajima E; Hutchinson J; Viscosi E; Blouin G; Weekes C; Rugo H; Moy B; Bardia A
    Oncologist; 2021 Oct; 26(10):827-834. PubMed ID: 34176192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sacituzumab Govitecan-hziy: An Antibody-Drug Conjugate for the Treatment of Refractory, Metastatic, Triple-Negative Breast Cancer.
    Seligson JM; Patron AM; Berger MJ; Harvey RD; Seligson ND
    Ann Pharmacother; 2021 Jul; 55(7):921-931. PubMed ID: 33070624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sacituzumab govitecan for hormone receptor-positive HER2-negative advanced breast cancer.
    Garrigos L; Camacho D; Perez-Garcia JM; Llombart-Cussac A; Cortes J; Antonarelli G
    Expert Rev Anticancer Ther; 2024 Oct; 24(10):949-958. PubMed ID: 39210557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sacituzumab govitecan for hormone receptor-positive and triple-negative breast cancers.
    Satti SA; Sheikh MS
    Mol Cell Pharmacol; 2023; 15(1):1-5. PubMed ID: 37090944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The European Medicines Agency review of sacituzumab govitecan for the treatment of triple-negative breast cancer.
    Michaleas S; Moreno Oliver A; Mueller-Berghaus J; Sarac SB; van der Elst ME; Müller-Egert S; Zander H; Enzmann H; Pignatti F
    ESMO Open; 2022 Jun; 7(3):100497. PubMed ID: 35642987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer.
    Rugo HS; Bardia A; Tolaney SM; Arteaga C; Cortes J; Sohn J; Marmé F; Hong Q; Delaney RJ; Hafeez A; André F; Schmid P
    Future Oncol; 2020 Apr; 16(12):705-715. PubMed ID: 32223649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer.
    Bardia A; Hurvitz SA; Rugo HS; Brufsky A; Cortes J; Loibl S; Piccart M; Cowden J; Spears P; Carey LA
    Future Oncol; 2021 Oct; 17(30):3911-3924. PubMed ID: 34467774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer.
    Wahby S; Fashoyin-Aje L; Osgood CL; Cheng J; Fiero MH; Zhang L; Tang S; Hamed SS; Song P; Charlab R; Dorff SE; Ricks TK; Barnett-Ringgold K; Dinin J; Goldberg KB; Theoret MR; Pazdur R; Amiri-Kordestani L; Beaver JA
    Clin Cancer Res; 2021 Apr; 27(7):1850-1854. PubMed ID: 33168656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.